| CYP2C19基因多态性对奥美拉唑临床疗效的研究进展 |
| |
| 引用本文： | 周学琴,段丽芳,张耀东,白瑶. CYP2C19基因多态性对奥美拉唑临床疗效的研究进展[J]. 中国药物应用与监测, 2010, 7(1): 55-57 |
| |
| 作者姓名： | 周学琴 段丽芳 张耀东 白瑶 |
| |
| 作者单位： | 北京大学深圳医院药剂科,广东,深圳,518036 |
| |
| 基金项目： | 2008年深圳市科技计划项目课题 |
| |
| 摘 要： | CYP2C19是细胞色素氧化酶P450的主要成分之一，因其活性存在显著的个体差异，表现为遗传多态性，从而产生血药浓度的个体差异。本文对CYP2C19基因型与奥美拉唑代谢、临床疗效及CYP2C19新突变对奥美拉唑的影响进行综述。根据基因型设计奥美拉唑给药方案，为，临床实行个体化给药、提高疗效、减少不良反应提供参考。
|
| 关 键 词： | S-美芬妥英羟化酶 奥美拉唑 基因多态性 剂量 个体化用药 |
Advance of CYP2C19 polymorphism on clinical efficacy of omeprazole |
| |
| ZHOU Xue-qin,DUAN Li-fang,ZHANG Yao-dong,BAI Yao. Advance of CYP2C19 polymorphism on clinical efficacy of omeprazole[J]. , 2010, 7(1): 55-57 |
| |
| Authors: | ZHOU Xue-qin DUAN Li-fang ZHANG Yao-dong BAI Yao |
| |
| Affiliation: | (Department of Pharmacy, Peking University Shenzhen Hospital, Shenzhen 518036, China) |
| |
| Abstract: | CYP2C 19 is one of the important cytochrome oxidase P450, the activity of which shows genetic polymorphism, manifesting different plasma concentrations in different individuals.New advances including the relationship between CYP2C19 gene polymorphism and metabolism of omeprazole, its clinical efficacy, and the effect of new mutation of CYP2C19 on omeprazole were reviewed.The dosage regimen was established on the basis of the CYP2C19 genotypes, which could provide reference for implementing individual medication, improving clinical efficacy and decreasing the occurrence of adverse drug reactions. |
| |
| Keywords: | CYP2C19 Omeprazole Polymorphism Dosage Personalized medicine |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
